1. Richard IH, Schiffer RB, Kurlan R. Anxiety and Parkinson's disease. J Neuropsychiatry Clin Neurosci 1996; 8(4):383-392.
2. Tandberg E, Larsen JP, Aarsland D, et al. The occurrence of depression in Parkinson's disease: a community based study. Arch Neurol 1996; 53(2):175-179.
3. Weintraub D, Moberg PJ, Duda JE, et al. Effect of psychiatric and other nonmotor symptoms on disability in Parkinson's disease. J Am Geriatr Soc 2004; 52(5):784-788.
4. Mathias JL. Neurobehavioral functioning of persons with Parkinson's disease. Appl Neuropsychol 2003; 10(2):57-68.
5. Norman S, Troster AI, Fields JA, et al. Effects of depression and Parkinson's disease on cognitive functioning. J Neuropsychiatry Clin Neurosci 2002; 14(1):31-36.
6. Cubo E, Bernard B, Leurgans S, et al. Cognitive and motor function in patients with Parkinson's disease with and without depression. Clin Neuropharmacol 2000; 23(6):331-334.
7. Routh LC, Black JL, Ahlskog JE. Parkinson's disease complicated by anxiety. Mayo Clin Proc 1987; 2(8):733-735.
8. Global Parkinson's Disease Survey (GPDS) Steering Committee. Factors impacting on quality of life in Parkinson's disease: results from an international survey. Mov Disord 2002; 17(1):60-67.
9. Hughes TA, Ross HF, Mindham RHS, et al. Mortality in Parkinson's disease and its association with dementia and depression. Acta Neurol Scand 2004; 110(2):118-123.
10. Marsh L, McDonald WM, Cummings J, et al. Provisional diagnostic criteria for depression in Parkinson's disease: Report of an NINDS/NIMH Work Group. Mov Disord 2006; 21(2):148-158.
11. Weintraub D, Moberg PJ, Duda JE, et al. Recognition and treatment of depression in Parkinson's disease. J Geriatr Psychiatry Neurol 2003; 16(3):178-183.
12. Meara J, Mitchelmore E, Hobson P. Use of the GDS-15 geriatric depression scale as a screening instrument for depressive symptomatology in patients with Parkinson's disease and their carers in the community. Age Ageing 1999; 28(1):35-38.
13. Lenze EJ, Mulsant BH, Shear NK, et al. Comorbid anxiety disorders in depressed elderly patients. Am J Psychiatry 2000; 157(5):722-728.
15. Shulman LM, Taback RL, Rabinstein AA, et al. Non-recognition of depression and other non-motor symptoms in Parkinson's disease. Parkinsonism Relat Dis 2002; 8(3):193-197.
16. Starkstein SE, Robinson RG, Leiguardia R, et al. Anxiety and depression in Parkinson's disease. Behav Neurol 1993; 6:151-154.
17. Stein MB, Heuser IJ, Juncos JL, et al. Anxiety disorders in patients with Parkinson's disease. Am J Psychiatry 1990; 147(2):217-220.
18. Menza MA, Robertson-Hoffman DE, Bonapace AS. Parkinson's disease and anxiety: comorbidity with depression. Biol Psychiatry 1993; 34(7):465-470.
19. Nuti A, Ceravolo R, Piccinni A, et al. Psychiatric comorbidity in a population of Parkinson's disease patients. Eur J Neurol 2004; 11(5):315-320.
21. Adkin AL, Frank JS, Jog MS. Fear of falling and postural control in Parkinson's disease. Mov Disord 2003; 18(5):496-502.
22. Shulman LM, Singer C, Bean JA, et al. Internal tremor in patients with Parkinson's disease. Mov Disord 1996; 11(1):3-7.
23. Schiffer RB, Kurlan R, Rubin A, et al. Evidence for atypical depression in Parkinson's disease. Am J Psychiatry 1988; 145(8):1020-1022.
24. Weisskopf MG, Chen H, Schwarzschild MA, et al. Prospective study of phobic anxiety and risk of Parkinson's disease. Mov Disord 2003; 18(6):646-651.
25. Shiba M, Bower JH, Maraganore DM, et al. Anxiety disorders and depressive disorders preceding Parkinson's disease: a case-control study. Mov Disord 2000; 15(4):669-677.
26. Racette BA, Hartlein JM, Hershey T, et al. Clinical features and comorbidity of mood fluctuations in Parkinson's disease. J Neuropsychiatry Clin Neurosci 2002; 14(4):438-442.
27. Witjas T, Kaphan E, Azulay JP, et al. Nonmotor fluctuations in Parkinson's disease: frequent and disabling. Neurology 2002; 59(3):408-413.
28. Friedenberg DL, Cummings JL. Parkinson's disease, depression, and the on-off phenomenon. Psychosomatics 1989; 30(1):94-99.
29. Lauterbach EC, Freeman A, Vogel RL. Correlates of generalized anxiety and panic attacks in dystonia and Parkinson disease. Cog Behav Neurol 2003; 16(4):225-233.
30. Richard IH, Frank S, McDermott MP, et al. The ups and downs of Parkinson disease: a prospective study of mood and anxiety fluctuations. Cogn Behav Neurol 2004; 17(4): 201-207.
31. Nissenbaum H, Quinn NP, Brown RG, et al. Mood swings associated with the "on-off " phenomenon in Parkinson's disease. Psychol Med 1987; 17(4):899-904.
32. Kerenyi LK, Ricaurte GA, Schretlen DJ, et al. Positron emission tomography of striatal serotonin transporters in Parkinson's disease. Arch Neurol 2003; 60(9):1223-1229.
33. Jellinger KA. Post mortem studies in Parkinson's disease—is it possible to detect brain areas for specific symptoms? J Neural Transm Suppl 1999; 56:1-29.
34. Halliday GM, Li YW, Blumbergs PC, et al. Neuropathology of immunohistochemically identified brainstem neurons in Parkinson's disease. Ann Neurol 1990; 27(4):373-385.
35. Remy P, Doder M, Lees A, et al. Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 2005; 128(Pt 6):1314-1322.
36. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR. 4th ed. Text Revised. Washington, DC: American Psychiatric Association Press, 2000.
37. Beck AT, Epstein N, Brown G, et al. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 1988; 56(6):893-897.
38. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 1983; 67(6):361-370.
39. Marinus J, Leentjens AF, Visser M, et al. Evaluation of the hospital anxiety and depression scale in patients with Parkinson's disease. Clin Neuropharmacol 2002;25(6):318-324.
40. Casacchia M, Zamponi A, Squitieri G, et al. Treatment of anxiety in Parkinson's disease with bromazepam [in Italian]. Riv Neurol 1975; 45(3):326-338.
41. Ludwig CL, Weinberger DR, Bruno G, et al. Buspirone, Parkinson's disease, and the locus ceruleus. Clin Neuropharmacol 1986; 9(4):373-378.
42. Menza M, Marin H, Kaufman K, et al. Citalopram treatment of depression in Parkinson's disease: the impact on anxiety, disability, and cognition. J Neuropsychiatry Clin Neurosci 2004; 16(3):315-319.
43. Tarczy MI, Szombathelyi E. Depression in Parkinson's disease with special regard to anxiety: experiences with paroxetine treatment [abstr]. Mov Disord 1998; 13(suppl 2):275.
44. Shulman LM, Singer C, Liefert R, Mellman T, Weiner WJ. Therapeutic effects of sertraline in patients with Parkinson's disease [abstr]. Mov Disord 1996; 11:12.
45. Chuang C, Fahn S. Dramatic benefit with clonazepam treatment of intractable anxiety and panic attacks in Parkinson's disease [abstr]. Mov Disord 2001; 16(suppl 1):S35.
46. Cumming RG, Le Couteur DG. Benzodiazepines and risk of hip fractures in older people: a review of the evidence. CNS Drugs 2003; 17(11):825-837.
47. Bloem BR, Grimbergen YA, Cramer M, et al. Prospective assessment of falls in Parkinson's disease. J Neurol 2001; 248(11):950-958.
48. Ried LD, Johnson RE, Gettman DA. Benzodiazepine exposure and functional status in older people. J Am Geriatr Soc 1998; 46(1):71-76.
49. Richard IH, Kurlan R. A survey of antidepressant drug use in Parkinson's disease. Neurology 1997; 49(4):1168-1170.
Anon Drug Facts and Comparisons. St. Louis: Facts and Comparisons; 2006. Masand PS, Gupta S. Long-term side effects of newer-generation antidepressants: SSRIs, venlafaxine, nefazodone, bupropion, and mirtazapine. Ann Clin Psychiatry 2002; 14(3): 175-182.
Gregorian RS, Golden KA, Bahce A, et al. Antidepressant-induced sexual dysfunction. Ann Pharmacother 2002; 36(10):1577-1589.
Shrivastava RK, Shrivastava S, Overweg N, et al. Amantadine in the treatment of sexual dysfunction associated with selective serotonin reuptake inhibitors. J Clin Psychophar-macol 1995; 15(1):83-84.
Gony M, Lapeyre-Mestre M, Montastruc JL. Risk of serious extrapyramidal symptoms in patients with Parkinson's disease receiving antidepressant drugs: a pharmacoepi-demiologic study comparing serotonin reuptake inhibitors and other antidepressant drugs. Clin Neuropharmacol 2003; 26(3):142-145.
van de Vijver DA, Roos RA, Jansen PA, et al. Start of a selective serotonin reuptake inhibitor (SSRI) and increase of antiparkinsonian drug treatment in patients on levodopa. Br J Clin Pharmacol 2002; 54(2):168-170.
Dell'Agnello G, Ceravolo R, Nuti A, et al. SSRIs do not worsen Parkinson's disease: evidence from an open-label, prospective study. Clin Neuropharmacol 2001; 24(4):221-227. Dzoljic E, Kovacevic I, Pokrajac M, Mijalovic M, Milosevic M, Kostic V. Plasma concentrations of fluoxetine and motor signs in patients with Parkinson's disease [abstr]. Mov Disord 2004; 19(suppl 9):S235.
Chung KA, Carlson NE, Nutt JG. Short-term paroxetine treatment does not alter the motor response to levodopa in PD. Neurology 2005; 64(10):1797-1798. Richard IH, Kurlan R, Tanner C, et al. Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Neurology 1997; 48(4):1070-1077. Schwid SR, the Parkinson Study Group. Safety of rasagiline in combination with serotonin reuptake inhibitors [abstr]. Ann Neurol 2005; 58(suppl 9):S56. Black K, Shea C, Dursun S, et al. Selective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic criteria. J Psychiatry Neurosci 2000; 25(3):255-261. Bonifati V, Fabrizio E, Cipriani R, et al. Buspirone in levodopa-induced dyskinesias. Clin Neuropharmacol 1994; 17(1):73-82.
Miller E, Berrios GE, Politynska BE. Caring for someone with Parkinson's disease: factors that contribute to distress. Int J Geriatr Psychiatry 1996; 11:263-268. Slawek J, Derejko M, Lass P. Factors affecting the quality of life of patients with idiopathic Parkinson's disease—a cross-sectional study in an outpatient clinic attendees. Parkinsonism Relat Disord 2005; 11(7):465-468.
Nilsson FM, Kessing LV, Sorensen TM, et al. Major depressive disorder in Parkinson's disease: a register-based study. Acta Psychiatr Scand 2002; 106(3):202-211. Nilsson FM, Kessing LV, Bolwig TG. Increased risk of developing Parkinson's disease for patients with major affective disorder: a register study. Acta Psychiatr Scand 2001; 104(5):380-386.
Slaughter JR, Slaughter KA, Nichols D, et al. Prevalence, clinical manifestations, etiology, and treatment of depression in Parkinson's disease. J Neuropsychiatry Clin Neurosci 2001; 13(2):187-196.
Leentjens AF, Marinus J, Van Hilten JJ, et al. The contribution of somatic symptoms to the diagnosis of depressive disorder in Parkinson's disease: a discriminant analytic approach. J Neuropsychiatry Clin Neurosci 2003; 15(1):74-77.
Naarding P, Leentjens AF, van Kooten F, et al. Disease-specific properties of the Hamilton Rating Scale for depression in patients with stroke, Alzheimer's dementia, and Parkinson's disease. J Neuropsychiatry Clin Neurosci 2002; 14(3):329-334. Leentjens AF, Verhey FR, Lousberg R, et al. The validity of the Hamilton and Montgomery-Asberg Depression Rating Scales as screening and diagnostic tools for depression in Parkinson's disease. Int J Geriatr Psychiatry 2000; 15(7):644-649. Rojo A, Aguilar M, Garolera MT, et al. Depression in Parkinson's disease: clinical correlates and outcome. Parkinsonism Relat Disord 2003; 10(1):23-28.
Leentjens AF, Lousberg R, Verhey FR. Markers for depression in Parkinson's disease. Acta Psychiatr Scand 2002; 106(3):196-201.
73. Schräg A, Jahanshahi M, Quinn NP. What contributes to depression in Parkinson's disease? Psychol Med 2001; 31(1):65-73.
74. Gotham AM, Brown RG, Marsden CD. Depression in Parkinson's disease: a quantitative and qualitative analysis. J Neurol Neurosurg Psychiatry 1986; 49(4):381-389.
75. Judd MM, Rapaport M, Paulus MB. Subsyndromal symptomatic depression: a new mood disorder? J Clin Psychiatry 1994; 55(suppl):18-28.
76. Ehmann TS, Beninger RJ, Gawel MJ, et al. Depressive symptoms in Parkinson's disease: a comparison with disabled control subjects. J Geriatr Psychiatry Neurol 1990; 3(1):3-9.
77. Brown R, Jahanshahi M. Depression in Parkinson's disease: a psychosocial viewpoint. Adv Neurol 1995; 65:61-84.
78. Huber SJ, Freidenberg DL, Paulson GW, et al. The pattern of depressive symptoms varies with progression of Parkinson's disease. J Neurol Neurosurg Psychiatry 1990; 53(4): 275-278.
79. Gonera EG, van't Hof M, Berger HJ, et al. Symptoms and duration of the prodromal phase in Parkinson's disease. Mov Disord 1997; 12(6):871-876.
80. Leentjens AF, Van den Akker M, Metsemakers JF, et al. Higher incidence of depression preceding the onset of Parkinson's disease: a register study. Mov Disord 2003; 18(4):414-418.
81. Piasecki SD, Jefferson JW. Psychiatric complications of deep brain stimulation for Parkinson's disease. J Clin Psychiatry 2004; 65(6):845-849.
82. Burn DJ, Troster AI. Neuropsychiatric complications of medical and surgical therapies for Parkinson's disease. J Geriatr Psychiatry Neurol 2004; 17(3):172-180.
83. Takeshita S, Kurisu K, Trop L, et al. Effect of subthalamic stimulation on mood state in Parkinson's disease: evaluation of previous facts and problems. Neurosurg Rev 2005; 28(3):179-186.
84. Berney A, Vingerhoets F, Perrin A, et al. Effect on mood of subthalamic DBS for Parkinson's disease: a consecutive series of 24 patients. Neurology 2002; 59(9):1427-1429.
85. Benabid AL, Koudsie A, Benazzouz A, et al. Deep brain stimulation of the corpus luysi (subthalamic nucleus) and other targets in Parkinson's disease. Extension to new indications such as dystonia and epilepsy. J Neurol 2001; 248(suppl 3):III37-III47.
86. Okun MS, Green J, Saben R, et al. Mood changes with deep brain stimulation of STN and GPi: results of a pilot study. J Neurol Neurosurg Psychiatry 2003; 74(11):1584-1586.
87. Doshi PK, Chhaya N, Bhatt MH. Depression leading to attempted suicide after bilateral subthalamic nucleus stimulation for Parkinson's disease. Mov Disord 2002; 17(5): 1084-1085.
88. Houeto JL, Mesnage V, Mallet L, et al. Behavioural disorders, Parkinson's disease and subthalamic stimulation. J Neurol Neurosurg Psychiatry 2002; 72(6):701-707.
89. Zgaljardic DJ, Borod JC, Foldi NS, et al. A review of the cognitive and behavioral sequelae of Parkinson's disease: relationship to frontostriatal circuitry. Cogn Behav Neurol 2003; 16(4):193-210.
90. Murai T, Muller U, Werheid K, et al. In vivo evidence for differential association of stri-atal dopamine and midbrain serotonin systems with neuropsychiatric symptoms in Parkinson's disease. J Neuropsychiatry Clin Neurosci 2001; 13(2):222-228.
91. Mayberg HS, Starkstein SE, Sadzot B, et al. Selective hypometabolism in the inferior frontal lobe in depressed patients with Parkinson's disease. Ann Neurol 1990; 28(1):57-64.
92. Starkstein SE, Preziosi TJ, Bolduc PL, et al. Depression in Parkinson's disease. J Nerv Ment Dis 1990; 178(1):27-31.
93. Weintraub D, Newberg AB, Cary MS, et al. Striatal dopamine transporter imaging correlates with anxiety and depression symptoms in Parkinson's disease. J Nucl Med 2005; 46(2):227-232.
94. Black KJ, Hershey T, Hartlein JM, et al. Levodopa challenge neuroimaging of levodopa-related mood fluctuations in Parkinson's disease. Neuropsychopharmacology 2005; 30(3):590-601.
95. Mayeux R, Stern Y, Cote L, et al. Altered serotonin metabolism in depressed patients with Parkinson's disease. Neurology 1984; 34(5):642-646.
96. Kuhn W, Muller T, Gerlach M, et al. Depression in Parkinson's disease: biogenic amines in CSF of "de novo" patients. J Neural Transm 1996; 103(12):1441-1445.
O'Suilleabhain PE, Sung V, Hernandez C, et al. Elevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associations. Arch Neurol 2004; 61(6):865-868.
Mossner R, Henneberg A, Schmitt A, et al. Allelic variation of serotonin transporter expression is associated with depression in Parkinson's disease. Mol Psychiatry 2001; 6(3):350-352.
Burn DJ, Tiangyou W, Allcock LM, et al. Allelic variation of a functional polymorphism in the serotonin transporter gene and depression in Parkinson's disease. Parkinsonism Relat Disord 2006; 12(3):139-41.
Menza MA, Palermo B, DiPaola R, et al. Depression and anxiety in Parkinson's disease: possible effect of genetic variation in the serotonin transporter. J Geriatr Psychiatry Neurol 1999; 12(2):49-52.
Barrero FJ, Ampuero I, Morales B, et al. Depression in Parkinson's disease is related to a genetic polymorphism of the cannabinoid receptor gene (CNR1). Pharmacogenomics J 2005; 5(2):135-141.
Gallo JJ, Rabins PV. Depression without sadness: alternative presentations of depression in late life. Am Fam Physician 1999; 60(3):820-826.
Cheng EM, Siderowf A, Swarztrauber K, et al. Development of quality of care indicators for Parkinson's disease. Mov Disord 2004; 19(2):136-150.
Schwenk TL. Diagnosis of late life depression: the view from primary care. Biol Psychiatry 2002; 52(3):157-163.
Starkstein SE, Preziosi TJ, Forrester AW, et al. Specificity of affective and autonomic symptoms of depression in Parkinson's disease. J Neurol Neurosurg Psychiatry 1990; 53(10):869-873.
Williams J. A structured interview guide for the Hamilton Depression Rating Scale. Arch Gen Psychiatry 1988; 45(8):742-747.
Montgomery SA, Asberg M. A new depression scale, designed to be sensitive to change. Br J Psychiatry 1979; 134:382-389.
Weintraub D, Oehlberg KA, Katz IR, et al. Test characteristics of the 15-item geriatric depression scale and hamilton depression rating scale in Parkinson disease. Am J Geri-atr Psychiatry 2006; 14(2):169-175.
Pignone MP, Gaynes BN, Rushton JL, et al. Screening for depression in adults: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002; 136(10):765-776.
Beck A, Steer R, Brown G. Manual for the Beck Depression Inventory. 2nd ed. San Antonio: The Psychological Corporation; 1996.
Yesavage JA. Geriatric depression scale. Psychopharmacol Bull 1988; 24(4):709-710. Zung W. A self-rating depression scale. Arch Gen Psychiatry 1965; 12:63-70. Radloff L. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1977; 1:385-401.
Visser M, Leentjens AF, Marinus J, et al. Reliability and validity of the Beck depression inventory in patients with Parkinson's disease. Mov Disord 2006; 21(5):668-72. Leentjens AF, Verhey FR, Luijckx GJ, et al. The validity of the Beck Depression Inventory as a screening and diagnostic instrument for depression in patients with Parkinson's disease. Mov Disord 2000; 15(6):1221-1224.
Levin BE, Llabre MM, Weiner WJ. Parkinson's disease and depression: psychometric properties of the Beck Depression Inventory. J Neurol Neurosurg Psychiatry 1988; 51(11):1401-1404.
Sheikh JI, Yesavage JA. Geriatric Depression Scale (GDS): recent evidence and development of a shorter version. In: Brink TL, ed. Clinical Gerontology: a Guide to Assessment and Intervention. New York: Haworth Press, 1986.
Ertan FS, Ertan T, Kiziltan G, et al. Reliability and validity of the Geriatric Depression Scale in depression in Parkinson's disease. J Neurol Neurosurg Psychiatry 2005; 76(10): 1445-1447.
Scheinthal SM, Steer RA, Giffin L, et al. Evaluating geriatric medical outpatients with the Beck Depression Inventory-Fast screen for medical patients. Aging Ment Health 2001; 5(2):143-148.
120. Okun MS, Walter BL, McDonald WM, et al. Beneficial effects of testosterone replacement for the nonmotor symptoms of Parkinson's disease. Arch Neurol 2002; 59(11):1750-1753.
121. Pintor L, Bailles E, Valldeoriola F, et al. Response to 4-month treatment with reboxetine in Parkinson's disease patients with a major depressive episode. Gen Hosp Psychiatry 2006; 28(1):59-64.
122. Takahashi H, Kamata M, Yoshida K, et al. Remarkable effect of milnacipran, a serotonin-noradrenalin reuptake inhibitor (SNRI), on depressive symptoms in patients with Parkinson's disease who have insufficient response to selective serotonin reuptake inhibitors (SSRIs): two case reports. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29:351-353.
123. Weintraub D, Taraborelli D, Duda JE, et al. Escitalopram for the treatment of major depression in Parkinson's disease: impact on depression, cognition, and motor function. Mov Disord 2004; 19(suppl 9):S188.
124. Bayulkem K, Torun F. Effectiveness of sertraline in treatment of depression with Parkinson's disease [abstr]. Mov Disord 2002; 17(suppl 5):S74.
125. Bayulkem K, Torun F. Therapeutic efficiency of venlafaxine in depressive patients with Parkinson's disease [abstr]. Mov Disord 2002; 7(suppl 5):S75.
126. Lemke MR. Effect of reboxetine on depression in Parkinson's disease patients. J Clin Psychiatry 2002; 63(4):300-304.
127. Rampello L, Chiechio S, Raffaele R, et al. The SSRI, citalopram, improves bradykinesia in patients with Parkinson's disease treated with L-dopa. Clin Neuropharmacol 2002; 25(1):21-24.
128. Aarsland D, Larsen JP, Lim NG, et al. a2-adrenoreceptor antagonism and serotonin reup-take inhibiton in patients with Parkinson's disease and depression. Nord J Psychiatry 2000; 54:411-415.
129. Ceravolo R, Nuti A, Piccinni A, et al. Paroxetine in Parkinson's disease: effects on motor and depressive symptoms. Neurology 2000; 55(8):1216-1218.
130. Leentjens AF, Verhey FR, Vreeling FW. Successful treatment of depression in a Parkinson disease patient with bupropion [in Dutch]. Ned Tijdschr Geneeskd 2000; 144(45): 2157-2159.
131. Rihmer Z, Satori M, Pestality P. Selegiline-citalopram combination in patients with Parkinson's disease and major depression. Int J Psychiatry Clin Pract 2000; 4:123-125.
132. Tesei S, Antoini A, Canesi M, et al. Tolerability of paroxetine in Parkinson's disease: a prospective study. Mov Disord 2000; 15(5):986-989.
133. Hauser RA, Zesiewicz TA. Sertraline for the treatment of depression in Parkinson's disease. Mov Disord 1997; 12(5):756-759.
134. Wittgens W, Donath O, Trenckmann U. Treatment of depressive syndromes in Parkinson's disease (P.D.) with paroxetine [abstr]. Mov Disord 1997; 12(suppl 1):128.
135. Meara RJ, Bhowmick BK, Hobson JP. An open uncontrolled study of the use of sertraline in the treatment of depression in Parkinson's disease. J Serotonin Res 1996; 4:243-249.
136. Montastruc JL, Fabre N, Blin O, et al. Does fluoxetine aggravate Parkinson's disease? a pilot prospective study. Mov Disord 1995; 10(3):355-357.
137. Mandell AJ, Markham C, Fowler W. Parkinson's syndrome, depression and imipramine: a preliminary report. Calif Med 1961; 95:12-14.
138. Strauss H. Office treatment of depressive states with a new drug (imipramine). NY State J Med 1959; 59:2906-2910.
139. Antonini A, Zecchinelli A, Tesei S, et al. A randomized single-blind study of sertraline vs. amitriptyline for the treatment of depression in patients with Parkinson's disease. Mov Disord 2004; 19(suppl 9):S263.
140. Fregni F, Santos CM, Myczkowski ML, et al. Repetitive transcranial magnetic stimulation is as effective as fluoxetine in the treatment of depression in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 2004; 75(8):1171-1174.
141. Weiser R, Hernandez-Rojas J, Flores J, et al. Efficacy, tolerability and safety of mirtazap-ine in the treatment of major depressive disorder due to Parkinson's disease. Mov Dis-ord 2004; 19(suppl 9):S205.
142. Avila A, Cardona X, Martin-Baranera M, et al. Does nefazodone improve both depression and Parkinson disease?: a pilot randomized trial. J Clin Psychopharmacol 2003; 23(5):509-513.
Leentjens AF, Vreeling FW, Luijckx GJ, et al. SSRIs in the treatment of depression in Parkinson's disease. Int J Geriatr Psychiatry 2003; 18(6):552-554.
Serrano-Duenas M. A comparison between low doses of amitriptyline and low doses of fluoxetin used in the control of depression in patients suffering from Parkinson's disease [in Spanish]. Rev Neurol 2002; 35(11):1010-1014.
Wermuth L, Sorensen PS, Timm B, et al. Depression in idiopathic Parkinson's disease treated with citalopram:a placebo-controlled trial. Nordic J Psychiatry 1998; 52(2): 163-169.
Steur EN, Ballering LA. Moclobemide and selegeline in the treatment of depression in Parkinson's disease. J Neurol Neurosurg Psychiatry 1997; 63(4):547. Rabey JM, Orlov E, Korczyn AD. Comparison of fluvoxamine versus amitriptyline for treatment of depression in Parkinson's disease [abstr]. Neurology 1996; 46:A374. Andersen J, Aabro E, Gulmann N, et al. Antidepressive treatment in Parkinson's dis-ease:a controlled trial of the effect of nortriptyline in patients with Parkinson's disease treated with L-dopa. Acta Neurol Scand 1980; 62(4):210-219.
Laitinen L. Desipramine in treatment of Parkinson's disease. Acta Neurol Scand 1969; 45(1):109-113.
Strang RR. Imipramine in treatment of Parkinson's disease: a double-blind placebo study. BMJ 1965; 2:33-34.
Gill HS, DeVane CL, Risch SC. Extrapyramidal symptoms associated with cyclic antidepressant treatment: a review of the literature and consolidating hypothesis. J Clin Psy-chopharmacol 1997; 17(5):377-389.
Vandel P, Bonin B, Leveque E, et al. Tricyclic antidepressant-induced extrapyramidal side effects. Eur Neuropsychopharmacol 1997; 7(3):207-212.
Di Rocco A, Rogers JD, Brown R, et al. S-Adenosyl-methionine improves depression in patients with Parkinson's disease in an open-label clinical trial. Mov Disord 2000; 15(6): 1225-1229.
Gordon PH, Pullman SL, Louis ED, et al. Mirtazapine in parkinsonian tremor. Parkinsonism Relat Disord 2002; 9(2):125-126.
Meco G, Fabrizio E, Di Rezze S, et al. Mirtazapine in L-dopa-induced dyskinesias. Clin Neuropharmacol 2003; 26(4):179-181.
Normann C, Hesslinger B, Frauenknecht M, et al. Psychosis during chronic levodopa therapy triggered by the new antidepressive drug mirtazapine. Pharmacopsychiatry 1997; 30(6):263-265.
Onofrj M, Luciano AL, Thomas A, et al. Mirtazapine induces REM sleep behavior disorder (RBD) in parkinsonism. Neurology 2003; 60(1):113-115.
Amsterdam JD. A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. J Clin Psychiatry 2003; 64(2):208-214.
Bodkin JA, Amsterdam JD. Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients. Am J Psychiatry 2002; 159(11): 1869-1875.
Bagdy G, Graf M, Anheuer ZE, et al. Anxiety-like effects induced by acute fluoxetine, sertraline or m-CPP treatment are reversed by pretreatment with the 5-HT2C receptor antagonist SB-242084 but not the 5-HT1A receptor antagonist WAY-100635. Int J Neuropsychopharmacol 2001; 4(4):399-408.
Reichmann H, Brecht MH, Koster J, et al. Pramipexole in routine clinical practice: a prospective observational trial in Parkinson's disease. CNS Drugs 2003; 17(13): 965-973.
Rektorova I, Rektor I, Bares M, et al. Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study. Eur J Neurol 2003; 10(4):399-406.
Lattanzi L, Dell'Osso L, Cassano P, et al. Pramipexole in treatment-resistant depression: a 16-week naturalistic study. Bipolar Disord 2002; 4(5):307-314.
Corrigan MH, Denahan AQ, Wright CE, et al. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress Anxiety 2000; 11(2):58-65. Perugi G, Toni C, Ruffolo G, et al. Adjunctive dopamine agonists in treatment-resistant bipolar II depression: an open case series. Pharmacopsychiatry 2001; 34:137-141.
166. Lemke MR, Brecht HM, Koester J, et al. Anhedonia, depression, and motor functioningin Parkinson's disease during treatment with pramipexole. J Neuropsychiatry Clin Neu-rosci 2005; 17(2):214-220.
167. Cassano P, Lattanzi L, Fava M, et al. Ropinirole in treatment-resistant depression: a 16-week pilot study. Can J Psychiatry 2005; 50:357-360.
168. Goetz CG, Koller WC, Poewe W, Rascol O, Sampaio C. Treatment of depression in idiopathic Parkinson's disease. Mov Disord 2002; 17(suppl 4):S112-S119.
169. Sa DS, Kapur S, Lang AE. Amoxapine shows an antipsychotic effect but worsens motor function in patients with Parkinson's disease and psychosis. Clin Neuropharmacol 2001; 24(4):242-243.
170. Coffey CE, Ross DR, Massey EW, et al. Dyskinesias associated with lithium therapy in parkinsonism. Clin Neuropharmacol 1984; 7(3):223-229.
171. Spina E, Scordo MG. Clinically significant drug interactions with antidepressants in the elderly. Drugs Aging 2002; 19(4):299-320.
172. Richelson E. Pharmacokinetic interactions of antidepressants. J Clin Psychiatry 1998; 59(suppl 10):22-26.
173. Flint AJ, Rifat SL Anxious depression in elderly patients. Response to antidepressant treatment. Am J Geriatr Psychiatry 1997; 5(2):107-115.
174. Alexopoulos GS, Myers BS, Young RC, et al. Recovery in geriatric depression. Arch Gen Psychiatry 1996; 53(4):305-312.
175. Mohr DC, Boudewynn C, Goodkin DE, et al. Comparative outcomes for individual CBT, supportive-expressive group psychotherapy and sertraline for the treatment of depression in multiple sclerosis. J Consult Clin Psychol 2001; 69:942-949.
176. Dobkin RD, Allen La, Menza M. Treating depression in Parkinson's disease: a cognitive-behavioral approach (abstract). Mov Disord 2006; 21(suppl 13):S129.
177. Cole K, Vaughan F. Brief cognitive behavioural therapy for depression associated with Parkinson's disease. A single case series. Behav Cogn Psychother 2005; 33:89-102.
178. Dreisig H, Beckmann JM, Wermuth L, et al. Psychological effects of structure cognitive psychotherapy in young patients with Parkinson disease: a pilot study. Nordic J Psychiatry 1999; 53:217-221.
179. Miller MD, Cornes C, Frank E, et al. Interpersonal psychotherapy for late-life depression: past, present, and future. J Psychother Pract Res 2001; 10(4):231-238.
180. Moellentine C, Rummans T, Ahlskog JE, et al. Effectiveness of ECT in patients with parkinsonism. J Neuropsychiatry Clin Neurosci 1998; 10(2):187-193.
181. Boggio PS, Fregni F, Bermpohl F, et al. Effect of repetitive TMS and fluoxetine on cognitive function inpatients with Parkinson's disease and concurrent depression. Mov Dis-ord 2005; 20(9):1178-1184.
182. Dragasevic N, Potrebic A, Damjanovic A, et al. Therapeutic efficacy of bilateral pre-frontal slow repetitive transcranial magnetic stimulation in depressed patients with Parkinson's disease: an open study. Mov Disord 2002; 17(3):528-532.
183. Pellecchia MT, Grasso A, Biancardi LG, et al. Physical therapy in Parkinson's disease: an open long-term rehabilitation trial. J Neurol 2004; 251(5):595-598.
Was this article helpful?
Stop Letting Anxiety Rule Your Life And Take Back The Control You Desire Right Now! You don't have to keep letting your anxiety disorder run your life. You can take back your inner power and change your life for the better starting today! In order to have control of a thing, you first must understand it. And that is what this handy little guide will help you do. Understand this illness for what it is. And, what it isn't.